• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

schizophrenia - Articles and news items

trevicta

EC approves Trevicta for the treatment of schizophrenia

Industry news / 1 June 2016 / Victoria White, Digital Content Producer

The EC has approved the use of Trevicta (paliperidone palmitate a 3-monthly injection) for the maintenance treatment of schizophrenia in adult patients…

schizophrenia

CHMP adopts positive opinion of Trevicta for maintenance treatment of schizophrenia

Industry news / 5 April 2016 / Victoria White

If approved, this 3‑monthly injection will allow patients to maintain an optimal level of treatment in their blood with fewer administrations…

Lu AF35700

Lundbeck starts Lu AF35700 Phase III programme in treatment-resistant schizophrenia

Industry news / 14 March 2016 / Victoria White

The Phase III programme will consist of two pivotal trials. Two doses of Lu AF35700 will be tested in patients with treatment resistant schizophrenia…

HTL9936

Positive Phase 1b results for Heptares’ HTL9936

Industry news / 10 February 2016 / Victoria White

HTL9936 is the first selective muscarinic M1 receptor agonist which has entered clinical development as a new treatment for cognitive impairment in patients with dementia and schizophrenia…

aristada

FDA approves schizophrenia treatment Aristada

Industry news / 7 October 2015 / Victoria White

Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection…

aripiprazole

New data released from QUALIFY study of aripiprazole once-monthly

Industry news / 24 June 2015 / Victoria White

Otsuka and Lundbeck have announced newly released subgroup analysis of data from the QUALIFY study of Abilify Maintena (aripiprazole once-monthly)…

schizophrenia

Johnson & Johnson and collaborators launch the Open Translational Science Project in Schizophrenia

Industry news / 9 June 2015 / Victoria White

Johnson & Johnson and a group of leading research organisations are launching the OPTICS Project – Open Translational Science in Schizophrenia…

RBP-7000-indivior

Positive top-line results from Phase 3 trial of RBP-7000 in schizophrenia announced

Industry news / 6 May 2015 / Victoria White

Indivior has announced top-line results from its Phase 3 clinical trial of RBP-7000, an investigational drug for the treatment of schizophrenia…

Pierre Fabre Pharmaceuticals starts Phase IIa trial for F17464

Pierre Fabre Pharmaceuticals announce initiation of Phase IIa clinical trial program for F17464 in schizophrenia

Industry news / 3 February 2015 / Pierre Fabre Pharmaceuticals

Pierre Fabre Pharmaceuticals has announced the initiation of a Phase IIa clinical trial program for F17464, a new selective dopamine D3 receptor antagonist, in schizophrenia. The trial is designed to assess the efficacy and safety of F17464 compared to placebo in patients with acute schizophrenia. The six-week multinational European trial will enroll 142 patients…

Janssen Pharmaceuticals Logo

New real-world data highlight health and financial impact of caring for an adult with schizophrenia

Industry news / 11 November 2014 / Janssen

Compared with their peers and other caregivers, carers for adults with schizophrenia report deteriorated physical and mental health and greater health resource usage/utilisation…

Human brain cells neurones

Lundbeck scientists part of group achieving breakthrough in understanding schizophrenia

Industry news, News / 23 December 2013 / Lundbeck

New research reveals that genetic variations that increase the risk of developing schizophrenia have a direct and harmful effect on the brain, impairing the intellectual and cognitive function of people with these variations…

H. Lundbeck A/S Logo 60x60

Otsuka and Lundbeck receive positive CHMP opinion for Abilify Maintena(r) in schizophrenia

Industry news, News / 21 September 2013 /

If approved by the European commission, Abilify Maintena would become the only dopamine D2 partial agonist in once-monthly injectable form for the maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +